Celcuity Inc
CELC39.500USD
+1.000+2.60%
Horário de mercado （ET）Cotações atrasadas em 15 min
1.49BValor de mercado
PerdaP/L TTM
Mais detalhes de Celcuity Inc Empresa
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Informações da empresa
Código da empresaCELC
Nome da EmpresaCelcuity Inc
Data de listagemSep 20, 2017
Fundado em2017
CEOMr. Brian F. Sullivan
Número de funcionários87
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 20
Endereço16305 36th Ave N Ste 100
CidadeMINNEAPOLIS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal55446-4285
Telefone17633920767
Sitehttps://www.celcuity.com/
Código da empresaCELC
Data de listagemSep 20, 2017
Fundado em2017
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.02M
+0.27%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
101.09K
--
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Mr. David F. Dalvey
Mr. David F. Dalvey
Independent Director
Independent Director
--
--
Dr. Charlotte Moser, M.D., Ph.D.
Dr. Charlotte Moser, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Leo T. Furcht, M.D.
Dr. Leo T. Furcht, M.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.02M
+0.27%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
101.09K
--
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Baker Bros. Advisors LP
10.94%
BVF Partners L.P.
8.91%
Sullivan (Brian F)
7.77%
Soleus Capital Management, L.P.
6.61%
Perceptive Advisors LLC
6.07%
Other
59.69%
Investidores
Investidores
Proporção
Baker Bros. Advisors LP
10.94%
BVF Partners L.P.
8.91%
Sullivan (Brian F)
7.77%
Soleus Capital Management, L.P.
6.61%
Perceptive Advisors LLC
6.07%
Other
59.69%
Tipos de investidores
Investidores
Proporção
Hedge Fund
37.76%
Investment Advisor
19.79%
Individual Investor
12.29%
Investment Advisor/Hedge Fund
10.89%
Private Equity
6.29%
Venture Capital
4.91%
Research Firm
1.98%
Corporation
0.92%
Pension Fund
0.09%
Other
5.09%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
212
36.06M
95.24%
-3.88M
2025Q1
215
36.05M
95.22%
-4.12M
2024Q4
205
35.54M
95.72%
-3.01M
2024Q3
191
34.97M
94.40%
-1.82M
2024Q2
174
33.96M
98.53%
+4.98M
2024Q1
164
26.84M
87.18%
+3.25M
2023Q4
146
21.83M
92.28%
-1.69M
2023Q3
148
21.82M
100.72%
+289.20K
2023Q2
156
20.45M
95.00%
-276.65K
2023Q1
152
18.61M
87.60%
-1.61M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Baker Bros. Advisors LP
4.26M
11.24%
+1.58M
+58.96%
Mar 31, 2025
BVF Partners L.P.
3.47M
9.15%
--
--
Mar 31, 2025
Sullivan (Brian F)
3.02M
7.99%
+8.15K
+0.27%
Apr 14, 2025
Soleus Capital Management, L.P.
2.57M
6.8%
+9.04K
+0.35%
Mar 31, 2025
Perceptive Advisors LLC
2.36M
6.24%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.03M
5.35%
+10.04K
+0.50%
Mar 31, 2025
The Vanguard Group, Inc.
1.67M
4.42%
+20.26K
+1.23%
Mar 31, 2025
Eventide Asset Management, LLC
1.27M
3.34%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
1.25M
3.3%
--
--
Mar 31, 2025
Laing (Lance G Ph.D.)
1.25M
3.3%
--
--
Mar 17, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
1%
iShares Genomics Immunology and Healthcare ETF
0.93%
ALPS Medical Breakthroughs ETF
0.37%
Tema Oncology ETF
0.26%
iShares Micro-Cap ETF
0.08%
iShares Russell 2000 Growth ETF
0.02%
iShares Russell 2000 ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
Ver Mais
Virtus LifeSci Biotech Clinical Trials ETF
Proporção1%
iShares Genomics Immunology and Healthcare ETF
Proporção0.93%
ALPS Medical Breakthroughs ETF
Proporção0.37%
Tema Oncology ETF
Proporção0.26%
iShares Micro-Cap ETF
Proporção0.08%
iShares Russell 2000 Growth ETF
Proporção0.02%
iShares Russell 2000 ETF
Proporção0.01%
Schwab U.S. Small-Cap ETF
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0.01%
ProShares Hedge Replication ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
